Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other financing activities: 2014-2024

Historic Other financing activities for Coherus Oncology (CHRS) over the last 10 years, with Dec 2024 value amounting to $2.5 million.

  • Coherus Oncology's Other financing activities fell 70.00% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 60.22%. This contributed to the annual value of $2.5 million for FY2024, which is 29.80% down from last year.
  • Coherus Oncology's Other financing activities amounted to $2.5 million in FY2024, which was down 29.80% from $3.5 million recorded in FY2023.
  • Coherus Oncology's 5-year Other financing activities high stood at $3.7 million for FY2022, and its period low was $880,000 during FY2020.
  • Over the past 3 years, Coherus Oncology's median Other financing activities value was $3.5 million (recorded in 2023), while the average stood at $3.2 million.
  • Its Other financing activities has fluctuated over the past 5 years, first soared by 113.58% in 2022, then declined by 29.80% in 2024.
  • Yearly analysis of 5 years shows Coherus Oncology's Other financing activities stood at $880,000 in 2020, then skyrocketed by 99.20% to $1.8 million in 2021, then soared by 113.58% to $3.7 million in 2022, then decreased by 5.80% to $3.5 million in 2023, then dropped by 29.80% to $2.5 million in 2024.